Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Picking Winners And Losers: Best Stocks To Buy Now
07:36pm, Friday, 17'th Apr 2020
The market rally should become more selective going forward. Risk reward continues to favor buying down days. Here are the top stocks to buy now.
ViewRay Announces Appointment of B. Kristine Johnson to its Board of Directors
08:01pm, Thursday, 16'th Apr 2020
ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors effective April 14, 2020.
AtriCure to Announce First Quarter 2020 Financial Results
12:00pm, Wednesday, 15'th Apr 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020
Time To Worry? Analysts Just Downgraded Their AtriCure, Inc. (NASDAQ:ATRC) Outlook
10:52am, Tuesday, 14'th Apr 2020
Market forces rained on the parade of AtriCure, Inc. (NASDAQ:ATRC) shareholders today, when the analysts downgraded...
Some Analysts Just Cut Their AtriCure, Inc. (NASDAQ:ATRC) Estimates
10:42am, Tuesday, 14'th Apr 2020
Market forces rained on the parade of AtriCure, Inc. (NASDAQ:ATRC) shareholders today, when the analysts downgraded...
AtriCure Sees Unusually High Options Volume (NASDAQ:ATRC)
10:34am, Tuesday, 14'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) was the target of some unusual options trading activity on Monday. Stock investors purchased 1,500 call options on the company. This represents an increase of approximately
Goldman Sachs Group Inc. Trims Position in AtriCure Inc. (NASDAQ:ATRC)
08:36am, Tuesday, 14'th Apr 2020
Goldman Sachs Group Inc. decreased its stake in AtriCure Inc. (NASDAQ:ATRC) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange C
AtriCure (NASDAQ:ATRC) Price Target Cut to $41.00 by Analysts at Canaccord Genuity
07:25am, Tuesday, 14'th Apr 2020
AtriCure (NASDAQ:ATRC) had its price target reduced by Canaccord Genuity from $51.00 to $41.00 in a report released on Monday morning, BenzingaRatingsTable reports. Canaccord Genuity currently has a b
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Atricure (ATRC)
01:46pm, Monday, 13'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Atricure (ATRC) with bullish
Analysts Offer Insights on Healthcare Companies: PolarityTE (NASDAQ: PTE) and Atricure (NASDAQ: ATRC)
01:46pm, Monday, 13'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (
PTE
–
Research Report
) and Atricure (
ATRC
–
Research Report
) with bullish sentiment
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial hav
Atricure (ATRC) Gets a Buy Rating from Canaccord Genuity
10:06am, Monday, 13'th Apr 2020
In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC), with a price target of $41.00. The
Atricure (ATRC) Gets a Buy Rating from Canaccord Genuity
10:06am, Monday, 13'th Apr 2020
In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC – Research Report),
Diversified Trust Co Purchases Shares of 7,725 AtriCure Inc. (NASDAQ:ATRC)
09:56am, Monday, 13'th Apr 2020
Diversified Trust Co purchased a new stake in AtriCure Inc. (NASDAQ:ATRC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional inv
